There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PDS Biotechnology (PDSB – Research Report) and Shattuck Labs (STTK – Research Report) with bullish sentiments.
PDS Biotechnology (PDSB)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on PDS Biotechnology today and set a price target of $21.00. The company’s shares closed last Thursday at $4.78, close to its 52-week low of $3.80.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PDS Biotechnology with a $20.00 average price target, which is a 309.0% upside from current levels. In a report issued on October 25, B.Riley Financial also reiterated a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Shattuck Labs (STTK)
In a report released today, Gil Blum from Needham maintained a Buy rating on Shattuck Labs, with a price target of $12.00. The company’s shares closed last Thursday at $2.17.
According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Shattuck Labs with a $14.00 average price target, which is a 525.0% upside from current levels. In a report issued on October 25, Berenberg Bank also maintained a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PDSB:
- PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
- PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
- Pds Biotechnology (PDSB) Q3 Earnings Cheat Sheet
- PDS announces preliminary study results of subset of patients in VERSATILE-002
- PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
